MyFinsight
Home
Blog
About
Contact
Maturity of investments
$42,000K
Proceeds from exercise of
2022 usd financing...
$3,833K
Proceeds from exercise of
options
$1,196K
Proceeds from issuance of
common shares under...
$276K
Proceeds from exercise of
pre-funded warrants
$4K
Net cash provided by
(used in) investing...
$42,000K
Net cash provided by
financing activities
$5,309K
Effect of exchange rate
changes on cash
$3K
Net
increase/(decrease) in cash and cash...
$4,681K
Canceled cashflow
$42,631K
Change in fair value of
2022 usd financing...
$20,046K
Stock-based compensation
$7,132K
Accrued expenses
$2,994K
Accounts payable
$1,780K
Change in fair value on
directors' deferred share...
-$1,030K
Amortization of discounts and
premiums on investments,...
-$591K
Prepaid and other
current assets
-$585K
Other non-cash
adjustments
$220K
Other noncurrent
assets
-$118K
Net cash used in
operating activities
-$42,631K
Canceled cashflow
$34,496K
Net loss
-$77,098K
Other liabilities,
long-term
$29K
Loss from operations
-$59,220K
Total other
income/(expense), net
-$17,878K
Research And Development
$41,484K
General And
Administrative
$17,736K
Back
Back
Cash Flow
Definium Therapeutics, Inc. (DFTX)
Definium Therapeutics, Inc. (DFTX)
source: myfinsight.com